{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:41:15Z","timestamp":1791423675808,"version":"4.3.3"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T00:00:00Z","timestamp":1606694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Context<\/jats:title><jats:p>Hypertension is a major cardiovascular risk factor related to increased mortality in acromegaly. Surgical cure of acromegaly is associated with improvement in blood pressure levels, however little is known about the effect of pegvisomant (PEGV) treatment in patients with hypertension. This analysis evaluates outcomes in patients with hypertension and acromegaly included in ACROSTUDY.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>ACROSTUDY is a global non-interventional surveillance study of long-term treatment with PEGV, monitoring its safety and efficacy. The cohort was retrospectively divided in two subgroups: patients with and without hypertension. Stepwise logistic regression and Kaplan-Meyer analyses were performed for testing predictors of mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The total cohort included 2,090 patients with acromegaly treated with PEGV who were followed for a median of 6.8 years (range up to 12.1 years). In ACROSTUDY there were 1,344 patients with hypertension (52.3% males). This subgroup was older, had a higher BMI, and higher prevalence of diabetes, hyperlipidemia, and cardiovascular disease (CVD) when compared to patients without hypertension. During ACROSTUDY, 68 deaths were reported in the hypertension cohort, vs 10 in the cohort without hypertension. Both CVD (p&amp;lt;0.0001) and anterior pituitary deficiencies (p=0.0105) at study entry independently predicted mortality in patients with acromegaly and hypertension; Kaplan-Meier analysis confirmed that CVD significantly impairs survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hypertension is common in patients with acromegaly and significantly increases mortality, especially when there is concomitant CVD. These data suggest that treatment goals should extend beyond IGF-I normalization, and include optimisation of substitution of pituitary deficiencies and scrutinous screening and treatment of CVD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2020.577173","type":"journal-article","created":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T05:43:05Z","timestamp":1606714985000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes"],"prefix":"10.3389","volume":"11","author":[{"given":"Greisa","family":"Vila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart Jan","family":"van der Lely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian J. C. M. M.","family":"Neggers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly M. K.","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Valluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Hey-Hadavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)","volume":"151","author":"Mestron","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2012.03.015","article-title":"Italian Study Group of Acromegaly. Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1210\/jc.2016-1937","article-title":"The mexican acromegaly registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes","volume":"101","author":"Portocarrero-Ortiz","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.82.4.3876","article-title":"Cardiac Involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension","volume":"82","author":"L\u00f3pez-Velasco","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020798430884","article-title":"Pathogenesis and prevalence of hypertension in acromegaly","volume":"4","author":"Bondanelli","year":"2001","journal-title":"Pituitary"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0253","article-title":"Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database","volume":"24","author":"Petrossians","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00120","article-title":"Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them","volume":"10","author":"Ramos-Lev\u00ed","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.8.8296","article-title":"Vascular function and blood pressure in GH transgenic mice","volume":"142","author":"Bohlooly-Y","year":"2001","journal-title":"Endocrinology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0002-8703(80)90277-X","article-title":"Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients","volume":"100","author":"Lie","year":"1980","journal-title":"Am Heart J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2570","article-title":"Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators. Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control","volume":"95","author":"Berg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031199","article-title":"Factors Influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.11.109","article-title":"Cardiovascular involvement in patients affected by acromegaly: an appraisal","volume":"167","author":"Mosca","year":"2013","journal-title":"Int J Cardiol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00509","article-title":"Insulin resistance in patients with acromegaly. Review","volume":"10","author":"Vila","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta- analysis of the effect of lowering serum levels of GH and IGF- I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-18-0255","article-title":"Mortality in acromegaly decreased in the last decade: a systematic review and meta-analysis","volume":"179","author":"Bolfi","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0794","article-title":"All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis","volume":"182","author":"Tritos","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2700","article-title":"Endocrine Society. Acromegaly: An Endocrine Society Clinical Practice Guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0333","article-title":"ACROSTUDY investigators. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY","volume":"161","author":"Brue","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-018-1792-0","article-title":"Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy","volume":"63","author":"Brue","year":"2019","journal-title":"Endocrine"},{"key":"B25","volume-title":"SAS\/STAT\u00ae Users Guide, Version 9","year":"2018"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.7.7635","article-title":"Acromegaly and cancer: not a problem","volume":"86","author":"Melmed","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0299","article-title":"Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy","volume":"93","author":"Colao","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12455","article-title":"The beneficial effect of acromegaly control on blood pressure values in normotensive patients","volume":"81","author":"Sardella","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B29","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1530\/EJE-13-0438","article-title":"Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels","volume":"171","author":"Droste","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2009.05.002","article-title":"Acromegaly in the elderly","volume":"70","author":"Dupuy","year":"2009","journal-title":"Ann Endocrinol (Paris)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1587","article-title":"Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance","volume":"92","author":"Pivonello","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001570","article-title":"Incidence of cardiovascular disease in individuals affected by recent changes to US blood pressure treatment guidelines","volume":"36","author":"Nayor","year":"2018","journal-title":"J Hypertens"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.005645","article-title":"Trends in mortality from all causes and cardiovascular disease among hypertensive and nonhypertensive adults in the United States","volume":"123","author":"Ford","year":"2011","journal-title":"Circulation"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.577173\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,30]],"date-time":"2020-11-30T05:43:07Z","timestamp":1606714987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2020.577173\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,30]]},"references-count":34,"alternative-id":["10.3389\/fendo.2020.577173"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.577173","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,30]]},"article-number":"577173"}}